The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic ...

U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer ...

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients ...

The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for its oral androgen receptor inhibitor ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

FDA approves Bayer's Nubeqa with ADT for metastatic hormone-sensitive prostate cancer, cutting death risk by 46%. Read more ...

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...